VITROLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 163.3 SEK | +3.62% |
|
-0.24% | -16.13% |
| Apr. 25 | Vitrolife AB Approves Dividend for the Financial Year 2023 | CI |
| Apr. 18 | Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest | DJ |
| Sales 2024 * | 3.6B 329M | Sales 2025 * | 3.98B 363M | Capitalization | 22.11B 2.02B |
|---|---|---|---|---|---|
| Net income 2024 * | 530M 48.45M | Net income 2025 * | 677M 61.88M | EV / Sales 2024 * | 6.31 x |
| Net Debt 2024 * | 600M 54.86M | Net cash position 2025 * | 103M 9.44M | EV / Sales 2025 * | 5.53 x |
| P/E ratio 2024 * |
41.7
x | P/E ratio 2025 * |
32.7
x | Employees | 1,132 |
| Yield 2024 * |
0.83% | Yield 2025 * |
0.85% | Free-Float | 55.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vitrolife AB
More news
| 1 day | +3.62% | ||
| 1 week | -0.24% | ||
| Current month | -18.76% | ||
| 1 month | -17.61% | ||
| 3 months | -6.53% | ||
| 6 months | +20.52% | ||
| Current year | -16.13% |
1 week
156.00
167.40
1 month
156.00202.40
Current year
156.00205.40
1 year
123.90244.20
3 years
123.90585.00
5 years
112.30585.00
10 years
20.75585.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bronwyn Brophy
CEO | Chief Executive Officer | - | 23-07-31 |
Patrik Tolf
DFI | Director of Finance/CFO | 54 | 21-12-31 |
| Chairman | 68 | 15-05-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 19-05-01 | |
| Chairman | 68 | 15-05-06 | |
| Director/Board Member | 64 | 18-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 233 M€ | +8.82% | ||
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 163.3 | +3.62% | 106,672 |
| 24-04-25 | 157.6 | -3.19% | 72,326 |
| 24-04-24 | 162.8 | -1.51% | 71,385 |
| 24-04-23 | 165.3 | +1.97% | 54,695 |
| 24-04-22 | 162.1 | -0.98% | 121,427 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-07-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
163.3
SEK
Average target price
231.7
SEK
Spread / Average Target
+41.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.13% | 2.02B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- VITR Stock
